Merck KGaA raises full-year forecast; Perlmutter’s new gig tackles ‘undruggable targets’
The Pharma Data
MAY 5, 2021
New variant-hardy AbCellera-Lilly mAb shows utility of viral genomics surveillance ( BioCentury ). Esker, a new biotech startup, launches with plans to make targeted immune drugs ( BioPharma Dive ). Microneedles are promising devices for painless drug delivery with minimal side effects ( EurekAlert ).
Let's personalize your content